Last updated: October 30, 2026
NitroMist is a prescription nitroglycerin lingual aerosol used for rapid relief or prevention of angina pectoris. Its commercial position is constrained by a small, mature market, multiple alternative nitroglycerin dosage forms, limited product differentiation, and the absence of meaningful remaining regulatory exclusivity. Public company filings do not separately disclose NitroMist revenue, so its financial trajectory must be assessed through product characteristics, competitive conditions, regulatory records, and market-access risks rather than reported SKU sales.
What is NitroMist and how does it work?
NitroMist contains nitroglycerin, a short-acting nitrate that relaxes vascular smooth muscle and reduces myocardial oxygen demand. Each metered spray delivers 0.4 mg of nitroglycerin sublingually or onto the tongue. The product is indicated for acute treatment of an angina attack and for prophylaxis before activities known to cause angina. [1]
NitroMist is a non-systemic, metered lingual aerosol. The dosage form is designed to provide rapid absorption without requiring the patient to swallow a tablet or wait for gastrointestinal absorption.
| Product attribute |
NitroMist profile |
| Active ingredient |
Nitroglycerin |
| Dosage form |
Metered lingual aerosol |
| Strength |
0.4 mg per spray |
| Primary use |
Acute angina relief and prophylaxis |
| FDA application |
NDA 021087 |
| Therapeutic class |
Nitrate antianginal |
| Regulatory category |
Small-molecule prescription drug |
| Reference market |
Nitroglycerin tablets, sprays, ointments, patches, and injectable products |
| Biosimilar exposure |
None |
The principal clinical advantage is delivery convenience. The principal commercial disadvantage is that the underlying molecule is old, inexpensive, and available in several competing forms.
What is the FDA regulatory status of NitroMist?
NitroMist received U.S. Food and Drug Administration approval under NDA 021087 in 2002. The FDA-approved labeling identifies nitroglycerin lingual aerosol as a treatment for acute angina and prevention of exertional angina. [1, 2]
The product is regulated as a conventional small-molecule drug. It is not a biologic and does not qualify for the biosimilar framework under the Public Health Service Act.
FDA regulatory milestones
| Event |
Date or status |
| FDA approval |
2002 |
| NDA |
021087 |
| Dosage form |
Metered lingual aerosol |
| Current regulatory pathway |
Approved NDA product |
| Pediatric exclusivity |
No publicly identified current pediatric exclusivity |
| Orphan-drug exclusivity |
Not applicable |
| New chemical entity exclusivity |
Expired |
| Patent-term extension relevance |
Any statutory extension would have expired before the current commercial period |
| Regulatory competition |
Generic or therapeutically substitutable nitroglycerin products |
The product’s regulatory value is therefore based on continued marketing, manufacturing reliability, brand recognition, and distribution rather than on active FDA exclusivity.
When does NitroMist lose exclusivity?
NitroMist’s meaningful exclusivity has already expired. The product was approved in 2002, and the five-year new chemical entity period associated with a qualifying new active ingredient would have ended no later than 2007. Any three-year clinical-investigation exclusivity would also have expired by that point. [2, 3]
No current regulatory exclusivity creates a material barrier to competing nitroglycerin products. NitroMist’s commercial protection depends mainly on product-specific manufacturing capability, device development, regulatory approval, branding, and distribution.
NitroMist exclusivity timeline
| Protection type |
Estimated end point |
Commercial effect today |
| New chemical entity exclusivity |
2007 or earlier |
Expired |
| Three-year clinical-investigation exclusivity |
2005 or earlier, if applicable |
Expired |
| Orphan exclusivity |
Not applicable |
None |
| Pediatric exclusivity |
No current public indication |
None |
| Patent exclusivity |
No material current protection identified in public product records |
Limited or none |
| Brand protection |
Ongoing only while trademark and commercial use continue |
Narrow |
The lack of active exclusivity means that a competitor does not need to wait for a patent or FDA exclusivity expiry before pursuing an equivalent or therapeutically substitutable product.
What patents protect NitroMist?
Publicly available FDA product records do not identify a material active patent estate that protects NitroMist’s commercial position. NitroMist is based on an established active ingredient and a conventional metered lingual aerosol platform.
The relevant intellectual-property categories are:
- The nitroglycerin compound, which is long established and not protectable as a new compound.
- The aerosol formulation, including concentration, propellant, solvent, and stability characteristics.
- The metered delivery system, including valve, actuator, container, and dose reproducibility.
- Manufacturing methods and filling processes.
- Trademark rights covering the NitroMist name.
The strongest potential barriers are likely to be technical and regulatory rather than molecule patents. A competitor must demonstrate consistent dose delivery, container compatibility, stability, extractables and leachables control, and reliable actuation across the product shelf life.
How strong is the NitroMist patent estate?
The patent estate is weak as a platform-level barrier because:
- Nitroglycerin has been used clinically for decades.
- Competing nitrate dosage forms are established.
- The product’s core clinical indication is conventional.
- A competitor can pursue a different formulation or delivery configuration.
- No current patent protection is prominently identified in the FDA product record for NDA 021087.
The device and formulation may still contain proprietary know-how. That know-how can increase development cost, but it is less durable than a valid composition-of-matter patent.
What formulations are protected by NitroMist?
NitroMist’s differentiation is linked to its metered lingual aerosol rather than to a novel chemical entity. The formulation must maintain a uniform 0.4 mg dose, provide acceptable spray performance, and preserve nitroglycerin stability throughout the labeled shelf life.
Potential formulation and device barriers include:
| Technical area |
Commercial relevance |
| Metering valve |
Controls dose uniformity |
| Actuator design |
Affects plume geometry and administration |
| Container system |
Limits chemical interaction and leakage |
| Solvent and propellant system |
Influences solubility and stability |
| Dose-counter or spray count |
Affects adherence and replacement timing |
| Packaging |
Protects against light, heat, and moisture |
| Manufacturing fill process |
Controls batch consistency |
| Stability profile |
Supports expiration dating and distribution |
These features can support regulatory differentiation, but they do not necessarily block a competing product. A generic manufacturer may develop a non-identical device that produces an equivalent clinical result and meets FDA requirements.
How does NitroMist compare with other nitroglycerin products?
NitroMist competes across dosage forms rather than only against another aerosol.
| Product category |
Typical use |
Relative commercial position |
| Nitroglycerin sublingual tablets |
Acute angina relief |
Low-cost, familiar, widely substitutable |
| Nitroglycerin lingual spray |
Acute relief and prophylaxis |
Convenient, device-dependent |
| Transdermal nitroglycerin patches |
Long-acting prophylaxis |
Not a direct substitute for acute attacks |
| Nitroglycerin ointment |
Prophylaxis |
Less convenient, variable application |
| Intravenous nitroglycerin |
Hospital use |
Separate institutional market |
| Isosorbide dinitrate |
Acute or preventive nitrate therapy |
Therapeutic alternative |
| Isosorbide mononitrate |
Chronic prophylaxis |
Not intended for rapid attack relief |
| Non-nitrate antianginals |
Long-term disease management |
Compete for treatment budget rather than identical use |
NitroMist’s main advantages are rapid administration, portability, and avoidance of tablet disintegration. Its disadvantages include higher device complexity, potentially higher price, handling requirements, and patient dependence on correct spray technique.
What is the competitive landscape for NitroMist?
The competitive landscape is fragmented and price-sensitive. NitroMist competes with branded and generic nitroglycerin products, as well as with other antianginal therapies.
Direct competition
The direct market includes nitroglycerin lingual aerosols and sprays. Product availability can vary by manufacturer, wholesaler, pharmacy channel, and supply conditions. A branded product may retain demand among patients and prescribers who prefer a spray, but substitution is easy when a comparable product is available.
Indirect competition
Indirect competitors include:
- Nitroglycerin sublingual tablets.
- Isosorbide dinitrate tablets.
- Isosorbide mononitrate extended-release products.
- Beta blockers.
- Calcium-channel blockers.
- Ranolazine.
- Revascularization procedures that reduce recurring angina.
The chronic management segment is more exposed to therapeutic substitution than the acute-relief segment. NitroMist is most defensible where patients value rapid, portable administration and have an established preference for aerosol delivery.
Which companies are challenging NitroMist?
No high-profile, publicly documented Paragraph IV litigation campaign directed specifically at NitroMist is identified in the available FDA product record and public patent data. The market risk is more likely to arise from ordinary generic competition, abbreviated new drug applications, product discontinuations, and channel substitution than from a major patent challenge.
What is the Paragraph IV risk?
Paragraph IV risk is limited by the apparent absence of a material unexpired patent barrier. A generic applicant could challenge listed patents if any were present in the Orange Book, but a significant litigation event would require an active listed patent and a commercial incentive to enter.
For NitroMist, the more relevant generic-entry questions are:
- Can a competitor reproduce the metered dose?
- Can it obtain acceptable stability data?
- Can it qualify its container and actuator?
- Can it secure sufficient manufacturing capacity?
- Is the market large enough to support development and launch costs?
- Can it obtain pharmacy and wholesaler access?
What is the Orange Book status of NitroMist?
NitroMist is associated with NDA 021087 in FDA product records. The Orange Book is the controlling source for current patent listings, exclusivity, and therapeutic-equivalence information. Publicly available product information does not indicate a current patent or exclusivity position capable of materially delaying competition. [2, 3]
A product can remain commercially marketed after its Orange Book exclusivity expires. Continued listing does not imply active patent protection.
What patent litigation affects NitroMist?
No material, publicly reported patent litigation involving NitroMist is identified in the cited FDA and public patent records. The absence of litigation is consistent with the product’s age, low molecular novelty, and limited commercial value relative to high-revenue medicines.
Potential disputes would more likely involve:
- Device equivalence.
- Trade dress or trademark rights.
- Manufacturing know-how.
- Product quality or supply obligations.
- ANDA approval or regulatory review.
- Distribution and contract rights.
These disputes would be less likely to produce a market-wide exclusion than litigation involving a patented active ingredient or protected drug-device combination.
What generic launch scenarios exist for NitroMist?
Three commercial scenarios are plausible.
Scenario 1: Limited generic entry
One or more competitors enter, but market participation remains narrow because the total aerosol market is small. Prices decline moderately, while the incumbent retains a portion of demand through brand familiarity and supply reliability.
Scenario 2: Rapid price erosion
Multiple manufacturers launch comparable sprays. Pharmacy substitution increases, wholesalers negotiate lower prices, and NitroMist loses share quickly. This scenario is more likely if the product has a simple approval pathway and manufacturing capacity is available.
Scenario 3: Brand persistence through supply and preference
NitroMist retains a premium position if competing products face manufacturing constraints, device-performance problems, or inconsistent availability. Brand persistence would depend on distribution and patient preference, not patent exclusivity.
The most probable outcome for a mature nitroglycerin aerosol is gradual erosion rather than a sudden patent-driven cliff. The rate depends on the number of approved competitors and whether pharmacies substitute automatically.
What manufacturing and intellectual-property barriers affect NitroMist?
The principal manufacturing barriers are modest but real. Nitroglycerin is potent at low doses, so dose uniformity and process control are important. Aerosol systems also require specialized filling, container qualification, valve testing, and stability validation.
Key barriers include:
- Low-dose content uniformity.
- Nitroglycerin adsorption or migration within the container system.
- Valve reproducibility.
- Spray performance after storage.
- Flammability and handling controls.
- Stability under temperature variation.
- Packaging compatibility.
- Commercial-scale aerosol filling.
- Regulatory validation of the drug-device combination.
These barriers can delay entry and increase development cost. They are unlikely to sustain high margins indefinitely because they do not prevent well-capitalized generic or specialty pharmaceutical manufacturers from entering.
What is the financial trajectory for NitroMist?
No public financial filing separately reports NitroMist net sales, gross margin, prescription volume, or operating profit. Product-level financial forecasting therefore requires a market model rather than reported company guidance.
The likely trajectory is mature or declining, with occasional upward movement caused by:
- Competitor shortages.
- Product discontinuations.
- Wholesaler stocking changes.
- Price increases in a low-volume specialty market.
- Contract wins or channel expansion.
- Temporary supply interruptions affecting alternative dosage forms.
Revenue can increase even while unit demand falls if list prices rise. That pattern would not indicate stronger underlying demand.
Financial drivers
| Driver |
Likely effect |
| Generic spray entry |
Lower price and market share |
| Brand recognition |
Supports retention among existing users |
| Alternative nitroglycerin tablets |
Limits pricing power |
| Manufacturing reliability |
Can preserve share during shortages |
| Pharmacy substitution |
Accelerates erosion |
| Small patient population |
Limits absolute revenue |
| Chronic angina treatment trends |
Reduce long-term growth potential |
| Hospital and outpatient channel mix |
Changes volume and reimbursement |
| Product discontinuations by competitors |
Can temporarily lift sales |
| Device manufacturing cost |
Pressures margin versus tablets |
Revenue exposure
NitroMist is unlikely to represent a material revenue driver for a diversified pharmaceutical company unless the product is held by a small specialty manufacturer or included in a focused cardiovascular portfolio. For a large pharmaceutical company, the product would generally be immaterial to consolidated revenue. For a smaller owner, it could have strategic value because an established prescription product can generate recurring cash flow without the clinical development expense associated with a new molecular entity.
Its financial value is therefore determined by:
- Net price after rebates.
- Annual prescription volume.
- Manufacturing cost.
- Cost of goods for the aerosol device.
- Sales and distribution expense.
- Working-capital requirements.
- Competitive product count.
- Supply continuity.
What licensing deals affect NitroMist?
No major publicly reported licensing transaction specifically tied to NitroMist is identified in the cited public regulatory records. Ownership, manufacturing, and distribution rights may change through private commercial agreements without producing a separately disclosed asset valuation.
Potential transaction structures include:
- Product acquisition by a specialty pharmaceutical company.
- Contract manufacturing and supply agreements.
- Regional distribution rights.
- Co-promotion arrangements.
- Portfolio sales involving multiple cardiovascular products.
Because NitroMist revenue is not separately disclosed, a transaction involving the product would likely be valued as part of a broader portfolio rather than on a standalone public revenue multiple.
What is the geographic coverage of NitroMist?
The strongest documented regulatory position is the U.S. NDA. U.S. approval does not establish approval in Europe, Canada, Japan, or other markets. International commercialization would require separate national or regional approvals, local labeling, manufacturing compliance, and distribution arrangements.
Geographic value is limited by the fact that nitroglycerin is widely available in other dosage forms worldwide. A U.S.-only product can still generate recurring revenue, but it has less strategic value than a product with broad international registrations or a protected global device platform.
Key Takeaways
- NitroMist is a 0.4 mg metered nitroglycerin lingual aerosol associated with FDA NDA 021087.
- Its approved uses are acute relief and prevention of angina pectoris.
- Regulatory exclusivity has expired, and no material active patent barrier is identified in the public product record.
- The product is not exposed to biosimilar competition because nitroglycerin is a small molecule.
- Competition comes from nitroglycerin tablets, other sprays, patches, ointments, injectable products, and alternative antianginal drugs.
- The principal barriers are device performance, low-dose manufacturing, stability, and FDA approval, not molecule patents.
- No major publicly documented Paragraph IV campaign or patent litigation is identified.
- Product-level revenue and profit are not separately disclosed in public filings.
- The likely financial trajectory is mature, with downside from generic entry and upside from competitor shortages or supply disruptions.
- NitroMist’s commercial value depends on manufacturing reliability, brand retention, and distribution rather than exclusivity.
FAQs About NitroMist Market and Patent Risk
Is NitroMist still commercially available?
NitroMist has an FDA-approved product record, but commercial availability can vary by manufacturer, pharmacy channel, wholesaler inventory, and regional supply conditions.
Is NitroMist interchangeable with nitroglycerin tablets?
It has the same active ingredient and a similar acute-relief purpose, but dosage form, administration technique, labeling, and FDA therapeutic-equivalence status determine whether automatic pharmacy substitution is permitted.
Can a generic manufacturer copy NitroMist?
A competitor may pursue an equivalent nitroglycerin aerosol or another approved spray product. It must establish product quality, dose delivery, stability, manufacturing control, and compliance with the applicable FDA pathway.
Does NitroMist have a biosimilar competitor?
No. Biosimilars apply to biological products. NitroMist contains the conventional small molecule nitroglycerin.
What would most increase NitroMist’s value?
The strongest near-term value drivers would be reliable supply during competitor shortages, durable pharmacy distribution, a defensible device advantage, and stable reimbursement. New molecule-level exclusivity is not a realistic value driver for this product.
References
- U.S. Food and Drug Administration. (2018). NitroMist (nitroglycerin) lingual aerosol: Prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: NitroMist, NDA 021087. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- DailyMed. (n.d.). NitroMist: Nitroglycerin aerosol, metered. National Library of Medicine.
